ArticleBMC infectious diseases2024
Talaromyces marneffei central nervous system infection unveiled by the novel Mp1p antigen detection assay in AIDS patient.
Article in BMC infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Development and Clinical Evaluation of a Novel Talaromyces marneffei Mp1p Lateral Flow Assay for Rapid Diagnosis of Talaromycosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Talaromyces marneffei infection of central nervous system in an immunocompetent child in a nonendemic area: a case report and literature review.BMC pediatrics · 2026Review
- Article
- Mp1p antigen as a sensitive diagnostic marker for early detection and treatment monitoring of Talaromyces Marneffei infection.BMC immunology · 2025Article
- An overview of rapid non-culture-based techniques in various clinical specimens for the laboratory diagnosis ofFrontiers in cellular and infection microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn acquired immunodeficiency syndrome patients, Talaromyces marneffei infections are mostly disseminated and may involve the skin, mucosa, respiratory system, digestive system, lymphatic system, and as some reports indicate, the nervous system. Mp1p, a cell wall-specific polysaccharide in Talaromyces marneffei, is used for laboratory diagnosis of Talaromyces marneffei in blood and urine samples. However, Cerebrospinal fluid Mp1p diagnosis of Talaromyces marneffei central nervous system infection has not been reported. CASE PRESENTATION: We present the case of an acquired immunodeficiency syndrome 35-year-old woman who has had dizziness and headache and was infected with central nervous system Talaromycosis.Magnetic resonance imaging scan which showed intracranial infectious lesions, altered brain atrophic, and periventricular demyelination.The Mp1p antigen was positive by using immunofluorescence in the Cerebrospinal fluid. Talaromyces marneffei was isolated from the Cerebrospinal fluid.After antifungal treatment, her clinical symptoms significantly improved.
conclusionsTalaromyces marneffei central nervous system infection is rare. If the patient has symptoms of central nervous system, the Cerebrospinal fluid Mp1p antigen and culture should be performed to make a definitive diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.